Cargando…
A c-Met Inhibitor Suppresses Osteosarcoma Progression via the ERK1/2 Pathway in Human Osteosarcoma Cells
INTRODUCTION: Osteosarcoma is the most common primary malignancy of the bone among adolescents and children. Despite intensive chemotherapy and aggressive surgery, the 5-year survival rate of osteosarcoma still falls under 70%, mainly due to its tendency to metastasize and to develop drug resistance...
Autores principales: | Chen, Weijie, Wu, Su, Huang, Yang, Zhang, Tingting, Dong, Hao, Zheng, Xing, Chen, Tao, Gong, Xiaokang, Liu, Gang, Zhao, Xing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440230/ https://www.ncbi.nlm.nih.gov/pubmed/34531665 http://dx.doi.org/10.2147/OTT.S317122 |
Ejemplares similares
-
Lipocalin-2 Inhibits Osteosarcoma Cell Metastasis by Suppressing MET Expression via the MEK–ERK Pathway
por: Lu, Ko-Hsiu, et al.
Publicado: (2021) -
Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma
por: Chen, Demeng, et al.
Publicado: (2018) -
Association of RDM1 with osteosarcoma progression via cell cycle and MEK/ERK signalling pathway regulation
por: Sheng, Jun, et al.
Publicado: (2021) -
Inhibition of BUB1 suppresses tumorigenesis of osteosarcoma via blocking of PI3K/Akt and ERK pathways
por: Huang, Zhen, et al.
Publicado: (2021) -
Hematopoietic cell kinase enhances osteosarcoma development via the MEK/ERK pathway
por: Liu, Weibo, et al.
Publicado: (2021)